Immune Checkpoint Inhibitor-induced Pancreatitis with Pancreatic Enlargement Mimicking Autoimmune Pancreatitis : A Case Report and Review of the Literature
A 61-year-old woman was administered 35 cycles of pembrolizumab for the treatment of recurrent endometrial cancer, achieving a complete response. She presented with asymptomatic pancreatic enlargement and elevated hepatobiliary enzymes, but amylase and lipase levels were within the normal ranges. Intrapancreatic bile duct stenosis due to pancreatic enlargement was present, mimicking autoimmune pancreatitis on computed tomography performed before the onset of clinical manifestations. A histological examination of a biopsy specimen showed lymphocyte and plasma cell infiltration with dense fibrosis in the stroma. The patient was successfully treated with oral prednisolone. There were no manifestations of recurrent pancreatitis after tapering the prednisolone dose.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Internal medicine (Tokyo, Japan) - 63(2024), 6 vom: 15. März, Seite 791-798 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tanabe, Kiyokuni [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9PHQ9Y1OLM |
|---|
| Anmerkungen: |
Date Completed 19.03.2024 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2169/internalmedicine.1943-23 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360322972 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360322972 | ||
| 003 | DE-627 | ||
| 005 | 20240425232325.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2169/internalmedicine.1943-23 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM360322972 | ||
| 035 | |a (NLM)37532549 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tanabe, Kiyokuni |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immune Checkpoint Inhibitor-induced Pancreatitis with Pancreatic Enlargement Mimicking Autoimmune Pancreatitis |b A Case Report and Review of the Literature |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.03.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A 61-year-old woman was administered 35 cycles of pembrolizumab for the treatment of recurrent endometrial cancer, achieving a complete response. She presented with asymptomatic pancreatic enlargement and elevated hepatobiliary enzymes, but amylase and lipase levels were within the normal ranges. Intrapancreatic bile duct stenosis due to pancreatic enlargement was present, mimicking autoimmune pancreatitis on computed tomography performed before the onset of clinical manifestations. A histological examination of a biopsy specimen showed lymphocyte and plasma cell infiltration with dense fibrosis in the stroma. The patient was successfully treated with oral prednisolone. There were no manifestations of recurrent pancreatitis after tapering the prednisolone dose | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ICI-induced pancreatitis | |
| 650 | 4 | |a autoimmune pancreatitis | |
| 650 | 4 | |a immune checkpoint inhibitors | |
| 650 | 4 | |a pancreatitis | |
| 650 | 4 | |a pembrolizumab | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a Prednisolone |2 NLM | |
| 650 | 7 | |a 9PHQ9Y1OLM |2 NLM | |
| 700 | 1 | |a Yokoyama, Kensuke |e verfasserin |4 aut | |
| 700 | 1 | |a Kanno, Atsushi |e verfasserin |4 aut | |
| 700 | 1 | |a Ikeda, Eriko |e verfasserin |4 aut | |
| 700 | 1 | |a Ando, Kozue |e verfasserin |4 aut | |
| 700 | 1 | |a Nagai, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Koyanagi, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Sakaguchi, Mio |e verfasserin |4 aut | |
| 700 | 1 | |a Nakaya, Takeo |e verfasserin |4 aut | |
| 700 | 1 | |a Tamada, Kiichi |e verfasserin |4 aut | |
| 700 | 1 | |a Niki, Toshiro |e verfasserin |4 aut | |
| 700 | 1 | |a Fukushima, Noriyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Lefor, Alan Kawarai |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Hironori |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Internal medicine (Tokyo, Japan) |d 1996 |g 63(2024), 6 vom: 15. März, Seite 791-798 |w (DE-627)NLM012606731 |x 1349-7235 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2024 |g number:6 |g day:15 |g month:03 |g pages:791-798 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2169/internalmedicine.1943-23 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2024 |e 6 |b 15 |c 03 |h 791-798 | ||